Stem Cell Clinic

FDA Approves First Maintenance Therapy for AML – Medscape

The US Food and Drug Administration (FDA) has approved an oral form of azacitidine (Onureg) for use as maintenance therapy for patients with acute myeloid leukemia (AML) who have achieved a first complete remission.

The approval extends to patients who have achieved complete remission with incomplete blood count recovery following intensive induction chemotherapy and who are unable to complete intensive curative therapy.

The approval was based on data from the QUAZAR AML-001 trial, which showed that oral azacitidine significantly improved overall survival when compared to placebo.

"It's not too hard to get these patients into remission," Harry P. Erba, MD, PhD, director of the Leukemia Program at the Duke Cancer Institute, Durham, North Carolina, told Medscape Medical News last year, when these results were first presented at the 2019 annual meeting of the American Society of Hematology. "The problem comes in keeping them in remission."

Despite various attempts, there has been no success over the past 30 years in defining maintenance treatment for these patients, Andrew H. Wei, MBBS, PhD, from the Alfred Hospital in Melbourne, Australia, said.

"Oral azacitidine represents a new therapeutic standard for patients with AML in remission," he said.

Azacitidine is a hypomethylating agent that incorporates into DNA and RNA. It has long been used as an injectable therapy for the treatment of myelodysplastic syndromes.

The approval of the new oral formulation for the new indication of AML "is the culmination of over a decade of research and 13 preclinical and clinical trials," said Giovanni Caforio, M.D., chairman and chief executive officer of Bristol-Myers Squibb, in a statement.

The QUAZAR AML-001 trial was a phase 3, international study involving 472 patients with AML who were within achieving a first complete remission or remission with incomplete blood recovery. All patients has received intensive induction chemotherapy with or without consolidation treatment, per investigator preference prior to study entry, and were not candidates for hematopoietic stem cell transplant at the time of screening.

Patients were randomly assigned to receive either oral azacitidine 200 mg daily on days 1 to 14 of a repeat 28-day cycle (n = 278) or matching placebo (n = 274). Treatment was continued indefinitely until blast count was more than 15% or patients experienced unacceptable toxicity or underwent transplant.

At a median follow-up of over 41.2 months, the median overall survival was significantly longer for patients who received oral azacitidine, at 24.7 monthsvs 14.8 months for those who received placebo (P < .0009; hazard ratio [HR], 0.69).

Relapse-free survival was also significantly prolonged to 10.2 months for patients who received oral azacitidinevs 4.8 months for those who received placebo (HR, 0.65; P < .0001).

Serious adverse reactions occurred in 15% of patients who received azacitidine. Events that occurred in 2% of patients include pneumonia (8%) and febrile neutropenia (7%). There was one fatal event.

The most common adverse reactions were nausea (65%, 24%), vomiting (60%, 10%), diarrhea (50%, 21%), fatigue/asthenia (44%, 25%), constipation (39%, 24%), pneumonia (27%, 17%), abdominal pain (22%, 13%) arthralgia (14%, 10%), decreased appetite (13%, 6%), febrile neutropenia (12%, 8%), dizziness (11%, 9%) and pain in extremity (11%, 5%). Permanent discontinuation because of an adverse reaction occurred in 8% of patients.

For more from Medscape Oncology, join us on Twitter and Facebook.

Link:
FDA Approves First Maintenance Therapy for AML - Medscape

Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients – Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. The panel session, entitled Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients, was held on September 2, 2020 and included international experts in hematology, oncology and complement science. The panel was moderated by Sara Jane Demy, founder and chief executive officer of Demy-Colton. A replay of the panel can be viewed here (free registration required).

The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and thrombosis seen in critically ill COVID-19 patients. Narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key effector of the lectin pathway of complement, was identified as a potentially highly effective therapy to treat critically ill COVID-19 patients.

Omeros previously announced positive results from the treatment with narsoplimab of six critically ill COVID-19 patients under a compassionate use protocol. All patients initially required mechanical ventilation and, following treatment with narsoplimab, all recovered, survived and were discharged from the hospital.

About Narsoplimab

Narsoplimab, also known as OMS721, is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.

Phase 3 clinical programs are in progress for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), in immunoglobulin A (IgA) nephropathy, and in atypical hemolytic uremic syndrome (aHUS). The FDA has granted narsoplimab breakthrough therapy designations for HSCT-TMA and for IgA nephropathy; orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies, for the treatment of HSCT-TMA and for the treatment of IgA nephropathy; and fast track designation for the treatment of patients with aHUS. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in HSCT and for treatment of primary IgA nephropathy.

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple late-stage clinical development programs focused on complement-mediated disorders, including COVID-19, and substance abuse. A rolling biologics license application for narsoplimab, the companys lead MASP-2 inhibitor, in hematopoietic stem cell transplant-associated thrombotic microangiopathy is being completed for submission to the U.S. FDA. Omeros also has a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the safe harbor created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, can, could, estimate, expect, goal, intend, likely, look forward to, may, on track, plan, potential, predict, project, prospects, scheduled, should, slated, targeting, will, would and similar expressions and variations thereof. Forward-looking statements, including statements regarding anticipated regulatory submissions, the timing and results of ongoing or anticipated clinical trials, and the therapeutic application of Omeros investigational product, are based on managements beliefs and assumptions and on information available to management only as of the date of this press release. Omeros actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, availability and timing of data from clinical trials and the results of such trials, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading Risk Factors in the companys Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (SEC) on March 2, 2020, as supplemented by its Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020 and subsequent filings with the SEC. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of any new information, future events or otherwise, except as required by applicable law.

More:
Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients - Business Wire

SoftWave Tissue Regeneration Technologies Receives FDA Clearance for the Treatment of Burn Wounds – PRNewswire

ATLANTA, Sept. 1, 2020 /PRNewswire/ --SoftWave Tissue Regeneration Technologies, a disruptive bio-medical device company, was cleared by the FDA on Friday, Aug. 28, 2020, for the treatment of superficial, partial-thickness, second-degree burns in adults (FDA 510k letter number K200926). SoftWave also has clearance for the treatment of Diabetic Foot Ulcers (DFU's), making it the only ESWT company to have two clearances for both acute (burns) and chronic wounds (DFU's). SoftWave therapy gives physicians, who treat burn patients, another option in healing burn wounds.

Each year, in the United States, approximately 450,000 patients receive medical attention, at emergency rooms, for burn related injuries. Most superficial wounds heal in two weeks; however, patients who suffer severe burns must endure intense physical and psychological pain during the burn injury treatment phase. There are over 3,400 burn injury deaths, including 1,100 children every year. The CDC estimates that $7.5 billion dollars are spent each year for burn related injuries. After the treatment phase is over and wounds are healed, scarring and disfigurement may interfere with movement, mobility, and daily life functions, resulting in a lifetime of physical and emotional burdens.

SoftWave's technology uses an unfocused extracorporeal shock wave (uESWT) to promote both a physical and biological response in order to improve wound healing. In a prospective randomized trial conducted by Dr. Christian Ottomann, published in the Annals of Surgery, significant accelerated epithelialization was demonstrated in the patients who had undergone uESWT (9.6 1.7 days) as compared to the patients who did not undergo uESWT (12.5 2.2 days); a statistically significant reduction in the days required for healing (3). This change is a substantial factor for any burn patient. The SoftWave biological response for wound healing is associated with neovascularization, and an increase in oxygenation and perfusion, ultimately resulting in angiogenesis. The hypothesized mechanisms of action for accelerated wound healing include stem cell activation and recruitment, and a reduction in the inflammation as proven in our published TLR3 model.

About SoftWave Tissue Regeneration Technologies

SoftWave TRT is a bio-medical device company that has proprietary patented technology, using unfocused acoustic waves, to treat a variety of conditions. The OrthoGold was first cleared in 2018 for the activation of connective tissue and registered for pain reduction and increased blood flow. Our second clearance, in 2019, was for the treatment of Diabetic Foot Ulcers. SoftWave TRT has over thirty patents for a variety of indications, including the following: stem cell activation, cellulite reduction, numerous indications involving the heart, and wound healing. SoftWave TRT plans to pursue FDA clearance, for all ESWT therapies, targeted by other publicly traded shockwave companies including Sanuwave (SNWV), Soliton (SOLY) and Shockwave Medical (SWAV). SoftWave believes our patented "softwaves" have superior benefits compared to traditional ESWT, and we are conducting multiple clinical trials to demonstrate the effectiveness over current available therapies.

Contact Us: [emailprotected] or call us at (888) 862-6162

Twitter: @SoftwaveTRT

Source: SoftWave Tissue Regeneration Technologies

Related Images

orthogold-100.jpg OrthoGold 100

Related Links

Softwave TRT

SOURCE SoftWave Tissue Regeneration Technologies

https://www.trtllc.com

More:
SoftWave Tissue Regeneration Technologies Receives FDA Clearance for the Treatment of Burn Wounds - PRNewswire

Mesoblast (ASX:MSB) granted ethics approval to treat COVID-19 patients in Australia – The Market Herald

Stem cell researcher Mesoblast (MSB) has been granted ethics approval for a trial of its remestemcel-L therapy in Australian COVID-19 patients.

Participating hospitals in Melbourne and Sydney will join 17 other facilities across the U.S. in the phase three trial in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome (ARDS).

ARDS is the leading cause of death associated with COVID-19. It occurs when the body's immune response gets caught in a runaway feedback loop which can cause organ and tissue damage.

Mesoblast's stem cell treatment has shown positive indications of reducing the inflammatory response in COVID-19 patients.

If the phase three trial is successful, remestemcel-L will be a step closer to being added to the growing arsenal medical practitioners have at their disposal to combat the disease.

Mesoblast CEO, Dr Silviu Itescu says it's important to gather as much data as possible as the pandemic continues unabated.

"As an Australian company developing a potential treatment for COVID-19 ARDS, the primary cause of death in patients infected with COVID-19, we have a responsibility to evaluate remestemcel-L in Australian patients as the country continues to grapple with COVID-19," Dr Itescu said.

The phase three trial was given the go-ahead based on results from a pilot study using remestemcel-L in patients under emergency compassionate care at Mt Sinai Hospital in New York.

Nine of the 12 patients with moderate-to-severe ARDS were successfully taken off a ventilator and discharged from hospital within a median of 10 days.

The new trial will test the treatment in ventilator-dependent patients in intensive care units with moderate-to-severe COVID-19 ARDS.

The trial will be randomised meaning some patients will receive a placebo instead of the remestemcel-L therapy. The results will consider mortality from all causes 30 days after the beginning of treatment.

The number of patients taken off ventilators in the trial period will also be considered in assessing the treatment's efficacy.

The independent Data Safety Monitoring Board (DSMB) plans to complete an interim analysis this month in the trials first 90 patients in the U.S. after they have completed 30 days of follow up.

Once that analysis is complete, the DSMB will make recommendations as to whether the trial should continue as planned or stop early.

Mesoblast is trading 0.38 per cent lower at $5.22 per share as at 12:27 pm AEST.

See the article here:
Mesoblast (ASX:MSB) granted ethics approval to treat COVID-19 patients in Australia - The Market Herald

Global Animal Stem Cell Therapy Market Size, Share, Technology, Included Features, Cost, Revenue, Manufacturers, Region, Applications and Forecast to…

Animal Stem Cell Therapy Market Data and Acquisition Research Study with Trends and Opportunities 2019-2024,The study of Animal Stem Cell Therapy market is a compilation of the market of Animal Stem Cell Therapy broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Animal Stem Cell Therapy industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Animal Stem Cell Therapy industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Animal Stem Cell Therapy Market report @ https://hongchunresearch.com/request-a-sample/74090

Key players in the global Animal Stem Cell Therapy market covered in Chapter 4:,ANIMAL CELL THERAPIES,Celavet,Animacel,VETSTEM BIOPHARMA,Cell Therapy Sciences,Magellan Stem Cells,Cells Power Japan,Animal Care Stem,Aratana Therapeutics,VetCell Therapeutics,MediVet Biologic,U.S. Stem Cell,J-ARM

In Chapter 11 and 13.3, on the basis of types, the Animal Stem Cell Therapy market from 2015 to 2026 is primarily split into:,Dogs,Horses,Others

In Chapter 12 and 13.4, on the basis of applications, the Animal Stem Cell Therapy market from 2015 to 2026 covers:,Veterinary Hospitals,Research Organizations

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:,North America (Covered in Chapter 6 and 13),United States,Canada,Mexico,Europe (Covered in Chapter 7 and 13),Germany,UK,France,Italy,Spain,Russia,Others,Asia-Pacific (Covered in Chapter 8 and 13),China,Japan,South Korea,Australia,India,Southeast Asia,Others,Middle East and Africa (Covered in Chapter 9 and 13),Saudi Arabia,UAE,Egypt,Nigeria,South Africa,Others,South America (Covered in Chapter 10 and 13),Brazil,Argentina,Columbia,Chile,Others

For a global outreach, the Animal Stem Cell Therapy study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:,Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitions,Revenue, cost price, capacity & utilizations, import/export rates and market share,Forecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Animal Stem Cell Therapy Market Report with [emailprotected] https://hongchunresearch.com/report/animal-stem-cell-therapy-market-size-2020-74090

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Animal Stem Cell Therapy Market

Chapter Four: Players Profiles

Chapter Five: Global Animal Stem Cell Therapy Market Analysis by Regions

Chapter Six: North America Animal Stem Cell Therapy Market Analysis by Countries

Chapter Seven: Europe Animal Stem Cell Therapy Market Analysis by Countries

Chapter Eight: Asia-Pacific Animal Stem Cell Therapy Market Analysis by Countries

Chapter Nine: Middle East and Africa Animal Stem Cell Therapy Market Analysis by Countries

Chapter Ten: South America Animal Stem Cell Therapy Market Analysis by Countries

Chapter Eleven: Global Animal Stem Cell Therapy Market Segment by Types

Chapter Twelve: Global Animal Stem Cell Therapy Market Segment by Applications 12.1 Global Animal Stem Cell Therapy Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Animal Stem Cell Therapy Sales and Market Share by Applications (2015-2020) 12.1.2 Global Animal Stem Cell Therapy Revenue and Market Share by Applications (2015-2020) 12.2 Veterinary Hospitals Sales, Revenue and Growth Rate (2015-2020) 12.3 Research Organizations Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Animal Stem Cell Therapy Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/74090

List of tables List of Tables and Figures Table Global Animal Stem Cell Therapy Market Size Growth Rate by Type (2020-2026) Figure Global Animal Stem Cell Therapy Market Share by Type in 2019 & 2026 Figure Dogs Features Figure Horses Features Figure Others Features Table Global Animal Stem Cell Therapy Market Size Growth by Application (2020-2026) Figure Global Animal Stem Cell Therapy Market Share by Application in 2019 & 2026 Figure Veterinary Hospitals Description Figure Research Organizations Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Animal Stem Cell Therapy Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Animal Stem Cell Therapy Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Animal Stem Cell Therapy Figure Production Process of Animal Stem Cell Therapy Figure Manufacturing Cost Structure of Animal Stem Cell Therapy Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table ANIMAL CELL THERAPIES Profile Table ANIMAL CELL THERAPIES Production, Value, Price, Gross Margin 2015-2020 Table Celavet Profile Table Celavet Production, Value, Price, Gross Margin 2015-2020 Table Animacel Profile Table Animacel Production, Value, Price, Gross Margin 2015-2020 Table VETSTEM BIOPHARMA Profile Table VETSTEM BIOPHARMA Production, Value, Price, Gross Margin 2015-2020 Table Cell Therapy Sciences Profile Table Cell Therapy Sciences Production, Value, Price, Gross Margin 2015-2020 Table Magellan Stem Cells Profile Table Magellan Stem Cells Production, Value, Price, Gross Margin 2015-2020 Table Cells Power Japan Profile Table Cells Power Japan Production, Value, Price, Gross Margin 2015-2020 Table Animal Care Stem Profile Table Animal Care Stem Production, Value, Price, Gross Margin 2015-2020 Table Aratana Therapeutics Profile Table Aratana Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table VetCell Therapeutics Profile Table VetCell Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table MediVet Biologic Profile Table MediVet Biologic Production, Value, Price, Gross Margin 2015-2020 Table U.S. Stem Cell Profile Table U.S. Stem Cell Production, Value, Price, Gross Margin 2015-2020 Table J-ARM Profile Table J-ARM Production, Value, Price, Gross Margin 2015-2020 Figure Global Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Global Animal Stem Cell Therapy Revenue ($) and Growth (2015-2020) Table Global Animal Stem Cell Therapy Sales by Regions (2015-2020) Table Global Animal Stem Cell Therapy Sales Market Share by Regions (2015-2020) Table Global Animal Stem Cell Therapy Revenue ($) by Regions (2015-2020) Table Global Animal Stem Cell Therapy Revenue Market Share by Regions (2015-2020) Table Global Animal Stem Cell Therapy Revenue Market Share by Regions in 2015 Table Global Animal Stem Cell Therapy Revenue Market Share by Regions in 2019 Figure North America Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Europe Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Asia-Pacific Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Middle East and Africa Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure South America Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure North America Animal Stem Cell Therapy Revenue ($) and Growth (2015-2020) Table North America Animal Stem Cell Therapy Sales by Countries (2015-2020) Table North America Animal Stem Cell Therapy Sales Market Share by Countries (2015-2020) Figure North America Animal Stem Cell Therapy Sales Market Share by Countries in 2015 Figure North America Animal Stem Cell Therapy Sales Market Share by Countries in 2019 Table North America Animal Stem Cell Therapy Revenue ($) by Countries (2015-2020) Table North America Animal Stem Cell Therapy Revenue Market Share by Countries (2015-2020) Figure North America Animal Stem Cell Therapy Revenue Market Share by Countries in 2015 Figure North America Animal Stem Cell Therapy Revenue Market Share by Countries in 2019 Figure United States Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Canada Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Mexico Animal Stem Cell Therapy Sales and Growth (2015-2020) Figure Europe Animal Stem Cell Therapy Revenue ($) Growth (2015-2020) Table Europe Animal Stem Cell Therapy Sales by Countries (2015-2020) Table Europe Animal Stem Cell Therapy Sales Market Share by Countries (2015-2020) Figure Europe Animal Stem Cell Therapy Sales Market Share by Countries in 2015 Figure Europe Animal Stem Cell Therapy Sales Market Share by Countries in 2019 Table Europe Animal Stem Cell Therapy Revenue ($) by Countries (2015-2020) Table Europe Animal Stem Cell Therapy Revenue Market Share by Countries (2015-2020) Figure Europe Animal Stem Cell Therapy Revenue Market Share by Countries in 2015 Figure Europe Animal Stem Cell Therapy Revenue Market Share by Countries in 2019 Figure Germany Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure UK Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure France Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Italy Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Spain Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Russia Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Asia-Pacific Animal Stem Cell Therapy Revenue ($) and Growth (2015-2020) Table Asia-Pacific Animal Stem Cell Therapy Sales by Countries (2015-2020) Table Asia-Pacific Animal Stem Cell Therapy Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Animal Stem Cell Therapy Sales Market Share by Countries in 2015 Figure Asia-Pacific Animal Stem Cell Therapy Sales Market Share by Countries in 2019 Table Asia-Pacific Animal Stem Cell Therapy Revenue ($) by Countries (2015-2020) Table Asia-Pacific Animal Stem Cell Therapy Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Animal Stem Cell Therapy Revenue Market Share by Countries in 2015 Figure Asia-Pacific Animal Stem Cell Therapy Revenue Market Share by Countries in 2019 Figure China Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Japan Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure South Korea Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Australia Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure India Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Southeast Asia Animal Stem Cell Therapy Sales and Growth Rate (2015-2020) Figure Middle East and Africa Animal Stem Cell Therapy Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer Gray Manager Global Sales + 852 8170 0792 [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Continued here:
Global Animal Stem Cell Therapy Market Size, Share, Technology, Included Features, Cost, Revenue, Manufacturers, Region, Applications and Forecast to...